PALIDO OD 6MG TABLET

Manufacturer : TOR-TORRENT PHARMA LTD
Composition : PALIPERIDONE-6MG
Dose Form : TABLET
Description : PALIDO-OD 6MG TAB
Route Of Administration : ORAL
Pack : 10
In stock
SKU
PAL0025
竄ケ112.10
Manufacturer : TOR-TORRENT PHARMA LTD
Composition : PALIPERIDONE-6MG
Dose Form : TABLET
Description : PALIDO-OD 6MG TAB
Route Of Administration : ORAL
Pack : 10

Drug Ingredient Information

PALIPERIDONE-6MG

PALIPERIDONE

Information for patients
Drug Information Paliperidone is an atypical antipsychotic. It may increase the risk of death when used to treat mental problems caused by dementia in elderly patients. Most of the deaths were linked to heart problems or infection. Paliperidone is not approved to treat mental problems caused by dementia.
Drug Alert
Alert should not be used to patients who are Hypersensitivity to paliperidone or risperidone.
Before Consuming the Medicine
Avoid Drug Increased risk of QT prolongation w/ class IA (e.g. quinidine, disopyramide) and class III (e.g. amiodarone, sotalol) antiarrhythmics. Additive effects w/ drugs that cause orthostatic hypotension (e.g. other antipsychotics, tricyclics). May antagonise actions of levodopa and other dopaminergics. Additive effect w/ drugs known to lower seizure threshold (e.g. phenothiazines or butyrophenones, clozapine, tricyclics or SSRIs, tramadol, mefloquine). May reduce plasma levels w/ carbamazepine. Enhanced central effects w/ other CNS depressants. May increase plasma levels w/ valproate. May affect the absorption w/ metoclopramide.
Drug Special Care Patient w/ known CV disease or family history of QT prolongation, history of seizures or other conditions that potentially lower the seizure threshold, predisposition to GI obstruction, possible prolactin-dependent tumours, Parkinson's disease. Cataract surgery. Elderly w/ dementia-related psychosis and risk factors for stroke. Renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and impairment of judgment, thinking or motor skills, if affected, avoid driving, operating machinery or performing hazardous tasks. Monitoring Parameters Monitor mental status changes, vital signs, wt, BP, electrolyte, renal and hepatic function. Closely monitor for worsening glucose control in patients w/ pre-existing DM.
Drug Drug Interactions Increased risk of QT prolongation w/ class IA (e.g. quinidine, disopyramide) and class III (e.g. amiodarone, sotalol) antiarrhythmics. Additive effects w/ drugs that cause orthostatic hypotension (e.g. other antipsychotics, tricyclics). May antagonise actions of levodopa and other dopaminergics. Additive effect w/ drugs known to lower seizure threshold (e.g. phenothiazines or butyrophenones, clozapine, tricyclics or SSRIs, tramadol, mefloquine). May reduce plasma levels w/ carbamazepine. Enhanced central effects w/ other CNS depressants. May increase plasma levels w/ valproate. May affect the absorption w/ metoclopramide.
Drug Pregnancy Interaction Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Drug Breast feeding Interaction no data
Drug Machinery Interaction no data
Drug More Information Paliperidone is a benzisoxazole atypical antipsychotic which is a main active metabolite of risperidone. It is an antagonist at dopamine D2, serotonin (5-HT2A), adrenergic (a1 and a2), and histamine (H1) receptors. Absorption: Bioavailability: 28%. Time to peak plasma concentration: Approx 24 hr (oral); approx 13 days (IM). Distribution: Plasma protein binding: 74% (mainly to a1-acid glycoprotein and albumin). Metabolism: Hepatic by CYP2D6 and CYP3A4 isoenzymes; minor metabolism via dealkylation, hydroxylation, dehydrogenation and benzisoxazole scission. Excretion: Via urine (80%) and faeces (11%). Elimination half-life: Approx 23 hr (oral); 25-49 days (IM).;
How to take the Medicine
Consumption Info
Drug quanitty PO Initial: 6 mg once daily in the morning. If necessary, adjust in increments of 3 mg over at least 5 days. Usual range: 3-12 mg/day. IM Initial: 150 mg on day 1, then 100 mg after a wk. Admin the 3rd dose 1 mth after the 2nd initiation dose. Mthly maintenance dose: 75 mg. Usual range: 25-150 mg.
Drug Dose May be taken with or without food. Take consistently either always w/ or always w/o food. Swallow whole, do not divide/chew/crush.
Excess Drug Consumption Drowsiness, sedation, tachycardia, hypotension, QT prolongation, extrapyramidal symptoms, torsades de pointes, ventricular fibrillation. Management: Symptomatic and supportive treatment. Establish and maintain a clear airway and ensure adequate oxygenation and ventilation. Treat hypotension and circulatory collapse w/ IV fluid and/or sympathomimetic agents. Consider gastric lavage and admin of activated charcoal w/ a laxative. In case of severe extrapyramidal symptoms, admin anticholinergic agents.
Forgot Drug Consumption
Stop Drug Consumption
Possible Side Effects
General Information Headache, dizziness, somnolence, sedation, agitation, fatigue, constipation, dyspepsia, dry mouth, nausea, vomiting, wt gain, akathisia, dystonia, hypertonia, tremor, tachycardia (including nasopharyngitis), blurred vision, orthostatic hypotension, arthralgia, back pain, pain in extremities, priapism, agranulocytosis, leucopenia, neutropenia. Rarely, tardive dyskinesia, small intestinal obstruction, hyperprolactinaemia resulting in gynaecomastia, menstrual disturbances, amenorrhoea, galactorrhoea.
Common Drug Side Effects Potentially Fatal: Neuroleptic malignant syndrome, CVA, transient ischaemic attacks.
Rare Drug Side Effects no data
Very Rare Drug Side Effects no data
Drug Side Effects Symptoms no data
How to Store the Medicine
How to Store the Medicine Store below 30ツーC. Protect from moisture.

Substitute Drugs

Write Your Own Review
You're reviewing:PALIDO OD 6MG TABLET
Your Rating

Get Captcha Image